Recent advances have seen a surge of new ideas and technologies to aid in the detection, treatment and further understanding of glaucoma. These technologies and advances are discussed to provide information on risk-factors, diagnosis and treatment. Glaucoma has never before seen such an advance in research and therapies coming forward in to the clinical workplace. It is an exciting time for physicians and researchers alike and over the next decade will certainly see advances in early detection, efficacious treatments and neuroprotection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724246 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Thioredoxin-interacting protein (TXNIP) inhibition promotes retinal ganglion cell survival and facilitates M1-like microglial transformation via the PI3K/Akt pathway in glaucoma.
Mol Med
December 2024
Department of Ophthalmology, Ruijin Hospital Affiliated Medical School, Shanghai Jiaotong University, 197 Ruijin er Road, Shanghai, 200025, China.
Background: Glaucoma is a group of heterogeneous neurodegenerative diseases with abnormal energy metabolism and imbalanced neuroinflammation in the retina. Thioredoxin-interacting protein (TXNIP) is involved in glucose and lipid metabolism, and associated with oxidative stress and inflammation, however, not known whether to be involved in glaucoma neuropathy and its underlying mechanisms.
Methods: To establish the chronic ocular hypertension (COH) mice model.
Racial and Gender Disparities for Glaucoma Treatment Rates in Upstate New York.
J Clin Med
November 2024
Department of Biostatistics and Computational Biology, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14642, USA.
Glaucoma is one of the leading causes of irreversible blindness around the world. Black individuals are two times more likely to be diagnosed with glaucoma compared to White individuals. In 2019, the prevalence of glaucoma in Monroe County was highest amongst older individuals aged 85 and non-Hispanic Blacks.
View Article and Find Full Text PDFEvaluation of Sustained Intraocular Pressure Elevations Across Antivascular Endothelial Growth Factor Agents.
J Vitreoretin Dis
December 2024
Cleveland Clinic Cole Eye Institute, Cleveland, OH, USA.
To evaluate the effect of antivascular endothelial growth factor (anti-VEGF) agents on the development of sustained intraocular pressure (IOP) elevations. This single-center retrospective cohort study included eyes receiving anti-VEGF injections for various indications along with nontreated fellow eyes from 2012 to 2022. Patients were grouped according to treatment with bevacizumab, ranibizumab, or aflibercept.
View Article and Find Full Text PDFProfile of Falls and Its Associated Factors among Adults with Visual Impairment: A Cross-sectional Study from a Tertiary Eye Hospital.
Indian J Public Health
October 2024
Professor and Principal, Elite School of Optometry and Sankara Nethralaya, Units of Medical Research Foundation, Chennai, Tamil Nadu, India.
Background: Falls among adults with visual impairment (VI) are underreported or underrepresented compared to elderly falls.
Objectives: To report falls among the young, middle-aged, and elderly adults with VI.
Materials And Methods: This cross-sectional study recruited subjects from a tertiary eye care center with VI aged ≥18 years based on clinical records.
Users of reimbursed glaucoma medications in Finland in 1986-2023: A nationwide study.
Acta Ophthalmol
December 2024
Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Purpose: The study evaluates the long-term trends in the number of patients using reimbursed glaucoma medications in Finland.
Methods: Reimbursement data of 193 082 new glaucoma patients in 1986-2023 were collected from the registry of Finnish Insurance Institution (Kela). The numbers of new, current and deceased users of reimbursed glaucoma medications in Finland at end of each year were analysed by gender and in different age groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!